Last reviewed · How we verify

DA-5204 — Competitive Intelligence Brief

DA-5204 (DA-5204) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Regenerative Medicine.

phase 3 Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

DA-5204 (DA-5204) — Seoul National University Hospital. DA-5204 is a regenerative medicine therapy designed to promote tissue repair and regeneration through stem cell or cellular mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DA-5204 TARGET DA-5204 Seoul National University Hospital phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DA-5204 — Competitive Intelligence Brief. https://druglandscape.com/ci/da-5204. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: